| Followers | 59 |
| Posts | 3257 |
| Boards Moderated | 0 |
| Alias Born | 05/15/2013 |
Monday, August 01, 2016 9:53:47 AM
I'm
In until
$30
In until
$30
Recent MCRB News
- Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/12/2026 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 02:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:05:06 AM
- Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease • GlobeNewswire Inc. • 05/04/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 08:10:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/27/2026 08:05:17 PM
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 • GlobeNewswire Inc. • 04/20/2026 11:00:00 AM
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 • GlobeNewswire Inc. • 04/20/2026 11:00:00 AM
- Seres Therapeutics to Present at CARB-X Investor Day • GlobeNewswire Inc. • 04/09/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 08:50:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:42:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 11:05:27 AM
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/12/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 10:39:08 PM
- Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:30:05 PM
- Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases • GlobeNewswire Inc. • 02/12/2026 12:00:00 PM
- Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy • GlobeNewswire Inc. • 01/06/2026 12:00:00 PM
- Seres Therapeutics to Participate in Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:30:04 PM
